Andrew W. Hahn, MD, presented “Treating Oligometastatic Prostate Cancer in the PSMA PET Era” during the 35th International Prostate Cancer Update conference on February 9, 2025, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Hahn, Andrew W. “Treating Oligometastatic Prostate Cancer in the PSMA PET Era.” February 9, 2025. Accessed May 2025. https://grandroundsinurology.com/treating-oligometastatic-prostate-cancer-in-the-psma-pet-era/
Treating Oligometastatic Prostate Cancer in the PSMA PET Era – Summary
Andrew W. Hahn, MD, Assistant Professor of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, Texas, addresses the treatment of oligometastatic prostate cancer in the PSMA PET era from a medical oncology perspective. In this 15-minute presentation, Dr. Hahn notes that oligometastatic disease, defined by up to five metastatic sites, is increasingly diagnosed due to improved imaging. While lesion count does not directly correlate with outcomes, disease biology and clinical presentation remain key factors in determining prognosis and treatment.
Dr. Hahn emphasizes the role of metastasis-directed therapy in delaying hormone therapy initiation, supported by data from trials like STOMP, ORIOLE, and XTEND. He recommends ADT combined with an AR pathway inhibitor for low-volume metastatic disease. Cases illustrating biochemical recurrence and de novo oligometastatic disease demonstrate the importance of tailored approaches, combining radiation with systemic therapy when appropriate.
Emerging studies focus on managing oligo-progressive disease to delay chemotherapy or radioligand therapy. Ongoing studies investigate optimal treatment strategies in this evolving space, particularly for oligo-progressive disease.
About the 35th International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 35 will feature lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts. You can learn more about the conference here.
ABOUT THE AUTHOR
Dr. Andrew Hahn is an Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center. Andrew earned a Bachelor of Arts in Synthetic Medicinal Chemistry and his Medical Doctorate at the University of Tennessee. Dr. Hahn completed Internal Medicine residency and a Chief Medicine Resident year at the University of Utah followed by his Medical Oncology fellowship at MD Anderson Cancer Center. His clinical focus is on prostate and kidney cancers. His research focus is to investigate how host factors influence response, resistance, and toxicity to cancer treatments and to design and run clinical trials to improve outcomes for patients with prostate and kidney cancer. Dr. Hahn has published over 40 peer-reviewed original research articles and authored or co-authored 30 other editorials, reviews, and book chapters. His work has been supported by an ASCO Conquer Cancer Foundation Young Investigator Award, Prostate Cancer Foundation Young Investigator Award, and a Department of Defense Early Investigator Research Award.
